Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Colorectal Cancer Clinical Trial

Official title:

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05593328
• Other study ID #: CRDF-003
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 17, 2023
• Est. completion date: April 2026

Study information

• Verified date: January 2024
• Source: Cardiff Oncology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil [5-FU], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 23
• Est. completion date: April 2026
• Est. primary completion date: November 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed metastatic and/or unresectable colorectal cancer (CRC).

2. Documentation of a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation in exon 2, 3, or 4 in primary tumor or metastasis, assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.

3. Age = 18 years.

4. Participants with tumors that have progressed on an oxaliplatin/fluoropyrimidine--based regimen with or without bevacizumab.

1. Participants must have had systemic therapy within 180 days of the screening visit.

2. Participants must have, at any time previously, received oxaliplatin-based chemotherapy with or without bevacizumab (= 6 weeks in duration).

3. Participants who received oxaliplatin/fluoropyrimidine-based neoadjuvant, adjuvant, and/or fluoropyrimidine maintenance or adjuvant therapy and have disease recurrence or progression > 6 months from their last dose of oxaliplatin will be required to have received oxaliplatin/fluoropyrimidine-based therapy with or without bevacizumab as first-line treatment for metastatic disease.

4. Participants who received an oxaliplatin-based regimen in the first-line setting and discontinued oxaliplatin because of toxicity or who received oxaliplatin for maintenance therapy are eligible as long as progression occurred < 6 months after the last dose of oxaliplatin therapy for advanced metastatic disease. It is recommended that these participants be re-challenged (if feasible) with oxaliplatin/fluoropyrimidine therapy and subsequently progress prior to eligibility. Participants with oxaliplatin-related neuropathy or oxaliplatin infusion-related hypersensitivity that cannot be rechallenged with oxaliplatin are eligible.

5. Participants must not have received prior treatment with irinotecan.

6. FOLFIRI therapy is appropriate for the participant as determined by the Investigator.

7. Imaging computed tomography (CT) or magnetic resonance imaging (MRI) of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within 28 days prior to the first dose of onvansertib. Only participants with measurable disease as defined per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) are eligible for enrollment. CT is the preferred imaging modality, but MRI is also accepted. All subsequent scans must consistently use the same imaging modality for comparison with the Screening scan throughout the study.

8. Must have acceptable organ function

9. Signed informed consent to provide blood sample(s) for specific correlative assays

Exclusion Criteria:

1. Concomitant KRAS or NRAS and BRAF-V600 mutation or Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR).

2. Anti-cancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug. The exception is a single dose of radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before enrollment, provided it is not the target lesion.

3. More than 1 prior chemotherapy regimen administered in the metastatic setting.

4. Major surgery within 6 weeks prior to enrollment.

5. Untreated or symptomatic brain metastasis.

6. Gastrointestinal (GI) disorder(s) that, in the opinion of the Investigator, would significantly impede the absorption of an oral agent (e.g., intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).

7. Unable or unwilling to swallow study drug.

8. Known hypersensitivity to fluoropyrimidine or leucovorin.

9. Known hypersensitivity to irinotecan.

10. Abnormal glucuronidation of bilirubin; known Gilbert's syndrome.

11. QT interval:

1. Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation that are readily corrected (e.g., medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility.

2. Planned concomitant use of medications known to prolong the QT/QTc interval according to institutional guidelines.

3. Presence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemia.

12. Use of strong cytochrome P450 3A4 (CYP3A4) or cytochrome P450 2C19 (CYP2C19) inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who can be switched to alternate therapy are not excluded. Inhibitors should be stopped at least 1 week prior to the first dose of protocol therapy and inducers should be stopped at least 2 weeks prior to initiation of protocol therapy.

13. The following are exclusion criteria for bevacizumab:

1. History of cardiac disease: Congestive heart failure (CHF) Class II or higher according to the New York Heart Association (NYHA); active coronary artery disease, myocardial infarction within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of participants who have been receiving therapy and are deemed by the Investigator to have stable/controlled disease.

2. Current uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management) and prior history of hypertensive crisis or hypertensive encephalopathy.

3. History of arterial thrombotic or embolic events (within 6 months prior to study entry).

4. Significant vascular disease (eg, aortic aneurysm, aortic dissection, symptomatic peripheral vascular disease).

5. Evidence of bleeding diathesis or clinically significant coagulopathy.

6. Major surgical procedure (including open biopsy, significant traumatic injury, etc) within 28 days, or anticipation of the need for major surgical procedure during the study, and minor surgical procedure (excluding placement of a vascular access device) within 7 days prior to study enrollment.

7. Proteinuria at Screening as demonstrated by urinalysis with proteinuria =2+ (participants discovered to have =2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =1 g of protein in 24 hours to be eligible).

8. Abdominal fistula, gastrointestinal perforation, peptic ulcer, or intra-abdominal abscess within the past 6 months.

9. Ongoing serious, non-healing wound, ulcer, or bone fracture

10. Known hypersensitivity to any component of bevacizumab

11. History of reversible posterior leukoencephalopathy syndrome

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Drug:
• Onvansertib
Oral capsule
• FOLFIRI
FOLFIRI (irinotecan + fluorouracil [5-FU] + leucovorin) as intravenous (IV) infusion
• Bevacizumab
IV infusion

Locations

Country	Name	City	State
United States	Pacific Cancer Medical Center	Anaheim	California
United States	Comprehensive Blood and Cancer Center - Bakersfield	Bakersfield	California
United States	Gabrail Cancer and Research Center	Canton	Ohio
United States	University of Virginia School of Medicine	Charlottesville	Virginia
United States	Trihealth Kenwood	Cincinnati	Ohio
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Englewood Health	Englewood	New Jersey
United States	Inova Schar Cancer Institute	Fairfax	Virginia
United States	San Juan Oncology Associates	Farmington	New Mexico
United States	West Cancer Center - East Campus	Germantown	Tennessee
United States	Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion	Grand Rapids	Michigan
United States	University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic - Jacksonville	Jacksonville	Florida
United States	Central Arkansas Radiation Therapy Institute - Cancer Center	Little Rock	Arkansas
United States	Cancer and Blood Specialty Clinic	Los Alamitos	California
United States	Norris Comprehensive Cancer Center	Los Angeles	California
United States	Manhattan Hematology Oncology Associates	New York	New York
United States	Nebraska Cancer Specialists - Midwest Cancer Center - Legacy	Omaha	Nebraska
United States	UCI Health - Chao Family Comprehensive Cancer Center	Orange	California
United States	Memorial Hospital West	Pembroke Pines	Florida
United States	Mayo Clinic in Arizona - Phoenix Campus	Phoenix	Arizona
United States	Mayo Clinic - Rochester	Rochester	Minnesota
United States	Washington University School of Medicine Center for Advanced Medicine	Saint Louis	Missouri
United States	Utah Cancer Specialists	Salt Lake City	Utah
United States	UCLA Health - Santa Monica Parkside Cancer Care	Santa Monica	California
United States	Torrance Memorial Physician Network - Cancer Care and Infusion Center	Torrance	California
United States	PIH Health	Whittier	California

Sponsors (1)

Lead Sponsor	Collaborator
Cardiff Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate	Defined as complete response (CR) or partial response (PR) as determined according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by an independent central review.	Up to approximately 2 years
Secondary	Progression-free Survival (PFS)	Defined from the date of first drug administration to progression or death, whichever occurs first.	Up to approximately 2 years
Secondary	Number of Participants with an Adverse Event (AE)	Type, incidence, causality and severity of AEs based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Clinically significant changes from baseline in vital signs, laboratory parameters, electrocardiograms (ECGs), physical examinations, weight, and Eastern Cooperative Oncology Group (ECOG) performance status will be recorded as AEs.	Up to approximately 2 years
Secondary	Disease Control Rate (DCR)	Defined as CR plus PR plus stable disease (SD).	Up to approximately 2 years
Secondary	Duration of Response (DOR)	Defined from the date of first response (CR or PR) to disease progression (PD) or death, whichever occurs first.	Up to approximately 2 years
Secondary	Overall Survival (OS)	Defined as the time from drug administration to death due to any cause.	Up to approximately 2 years
Secondary	Overall Response (OR)	Defined as CR or PR, PFS, DCR, DOR, and OS associated with a reduction in mutation allele frequency (MAF).	Up to approximately 2 years
Secondary	Maximum Concentration (Cmax) of Onvansertib		Day 1 and Day 5 of Cycle 1, and Day 5 of Cycle 3 (cycle is 28 days)
Secondary	Area Under The Plasma Concentration Curve (AUC) of Onvansertib		Day 1 and Day 5 of Cycle 1, and Day 5 of Cycle 3 (cycle is 28 days)
Secondary	Trough Concentration (Ctrough) of Onvansertib		Day 1 and Day 5 of Cycle 1, and Day 5 of Cycle 3 (cycle is 28 days)
Secondary	Maximum Concentration (Cmax) of Onvansertib Metabolites		Day 1 and Day 5 of Cycle 1, and Day 5 of Cycle 3 (cycle is 28 days)
Secondary	Area Under The Plasma Concentration Curve (AUC) of Onvansertib Metabolites		Day 1 and Day 5 of Cycle 1, and Day 5 of Cycle 3 (cycle is 28 days)
Secondary	Trough Concentration (Ctrough) of Onvansertib Metabolites		Day 1 and Day 5 of Cycle 1, and Day 5 of Cycle 3 (cycle is 28 days)
Secondary	Efficacy: Exposure Response Evaluation of Onvansertib	Correlation between onvansertib exposure and overall response rate.	Up to approximately 2 years
Secondary	Safety: Exposure Response Evaluation of Onvansertib	Correlation between onvansertib exposure and the number of participants with an AE.	Up to approximately 2 years